raav1.cmv.hufollistatin344
Gene therapyexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01519349)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Growth/differentiation factor 8INHIBITOR
MSTN inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- raav1.cmv.hufollistatin344
- raav1.cmv.hufollistin344
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02354781 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Duchenne Alliance, Milo Therapeutics, Ohio State University, Sarepta Therapeutics |
| NCT01519349 | Phase 1 | Jan 1, 2012 | Ohio State University, Parent Project Muscular Dystrophy, The Myositis Association |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ohio State University | Academic/Hospital | 2 | 1 | 2 | 2012 |
| Duchenne Alliance | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Milo Therapeutics | For profit | 1 | 0 | 1 | 2015 |
| Parent Project Muscular Dystrophy | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Sarepta Therapeutics | For profit | 1 | 1 | 1 | 2015 |
| The Myositis Association | Academic/Hospital | 1 | 0 | 1 | 2012 |
6 organizations
Page 1 / 1